NICOTINE POLACRILEX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NICOTINE POLACRILEX (NICOTINE POLACRILEX). Information on pregnancy safety and clinical dosing.
Nicotine polacrilex acts as a nicotinic acetylcholine receptor agonist, binding to α4β2 receptors in the ventral tegmental area and mediating dopamine release in the nucleus accumbens, which reduces withdrawal symptoms and cravings by providing a lower and slower peak of nicotine compared to smoking.
| Metabolism | Primarily hepatic metabolism via CYP2A6 (major) and CYP2B6 (minor) to cotinine and other metabolites; also undergoes glucuronidation via UGT2B10. |
| Excretion | Nicotine and its metabolites are primarily excreted renally. About 10-20% of nicotine is excreted unchanged in urine, with the remainder as metabolites, mainly cotinine. Urinary pH affects excretion; acidic urine increases clearance. Biliary/fecal excretion is negligible (<5%). |
| Half-life | The terminal elimination half-life of nicotine is approximately 2 hours (range 1-4 hours) after intravenous administration or smoking, but after polacrilex gum use, absorption is slower and half-life may be slightly prolonged due to continued absorption. Clinical context: short half-life necessitates frequent dosing to maintain levels for smoking cessation. |
| Protein binding | Nicotine is approximately 5-10% bound to plasma proteins, primarily albumin. Low binding means distribution is extensive. |
| Volume of Distribution | Volume of distribution for nicotine is approximately 1-2 L/kg, indicating extensive tissue distribution. It accumulates in tissues with high blood flow (brain, liver, kidneys). |
| Bioavailability | Bioavailability of nicotine from polacrilex gum is about 50-80% (variable due to buccal absorption and swallowing). Compared to smoking where bioavailability is nearly 100% but first-pass metabolism is avoided; oral ingestion of gum results in first-pass metabolism reducing systemic availability. |
| Onset of Action | Onset of action for nicotine polacrilex gum is 15-30 minutes after chewing, as nicotine is absorbed buccally. Slower than inhaled nicotine (which is seconds), but faster than transdermal patches (hours). |
| Duration of Action | Duration of action after nicotine polacrilex gum is approximately 1-2 hours, depending on dose and chewing technique. Used as needed to manage cravings; shorter than patches (24 hours) or nasal spray (1-2 hours). |
2 mg or 4 mg lozenge or gum as needed up to 20 lozenges or pieces of gum per day; typical dosing: 1 lozenge or piece of gum every 1-2 hours while awake, up to 12 per day. For smoking cessation, initial dose based on smoking habits: if first cigarette within 30 minutes of waking, use 4 mg; if >30 minutes, use 2 mg.
| Dosage form | TROCHE/LOZENGE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR ≥30 mL/min). For severe renal impairment (eGFR <30 mL/min), use with caution; nicotine clearance may be reduced, consider starting with lower dose and monitoring for adverse effects. |
| Liver impairment | No specific dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). For severe hepatic impairment (Child-Pugh C), use with caution; consider dose reduction due to potential decreased clearance. |
| Pediatric use | Not recommended for use in children and adolescents under 18 years of age due to lack of safety and efficacy data. For adolescents (12-17 years) with tobacco dependence, use only under healthcare provider supervision; dosing similar to adults but starting with 2 mg and adjusting based on response and tolerance. |
| Geriatric use | No specific dose adjustment required; elderly patients may be more sensitive to adverse effects. Start with lowest effective dose (2 mg) and titrate slowly. Monitor for dizziness, nausea, and other side effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NICOTINE POLACRILEX (NICOTINE POLACRILEX). Information on pregnancy safety and clinical dosing.
| Breastfeeding | Nicotine is excreted into breast milk; M/P ratio approximately 2.9. Higher nicotine concentrations may cause adverse effects in the infant (e.g., irritability, tachycardia). Avoid breastfeeding during nicotine polacrilex use; consider timing after dosing or alternative smoking cessation methods. |
| Teratogenic Risk | Nicotine polacrilex is associated with fetal risks, including reduced fetal growth, increased risk of preterm delivery, and potential neurobehavioral effects. Nicotine crosses the placenta and can cause fetal hypoxia due to vasoconstriction. Use during pregnancy is not recommended; however, smoking cessation benefits may outweigh risks. First trimester: potential for spontaneous abortion. Second and third trimesters: risk of placental vasoconstriction, reduced uterine blood flow, and fetal tobacco syndrome. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to nicotine or any component","Acute coronary syndrome or recent myocardial infarction (within 2 weeks)","Uncontrolled arrhythmias","Pregnancy (only if benefit outweighs risk; alternative therapies preferred)","Breastfeeding (nicotine excreted in breast milk)"]
| Precautions | ["Dependence: prolonged use may lead to physical dependence; gradual tapering recommended.","Cardiovascular: caution in patients with coronary artery disease, recent MI, or arrhythmias (especially with concurrent smoking).","Oral irritation: gingivitis, stomatitis, or jaw pain reported.","Accidental exposure: keep out of reach of children (toxic if ingested)."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and nicotine withdrawal symptoms. Assess fetal growth via ultrasound and fetal heart rate monitoring. Evaluate for signs of preterm labor. Monitor for fetal hypoxia if high doses used. |
| Fertility Effects | Nicotine may reduce fertility in both sexes; in women, it can impair ovulation and tubal function; in men, it may reduce sperm count and motility. Smoking cessation improves fertility outcomes. Nicotine polacrilex may aid cessation and thus indirectly improve fertility. |